home contact Site Map Corporate Website Search Value through Innovation April 4, 2021 News About company Social Responsibility Products Information for Patients Career contact Drug safety Medical information Commercial information Selected key information on the use of Pradaxa ® (dabigatran etexilate) Pradaxa - educational package No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player Prix Galien Award Business credibility Certificate of business credibility Top Employer Polska 2016 Top Employer Polska 2016 Communication to healthcare professionals News 27/01/2016 Afatinib from Boehringer Ingelheim demonstrated longer progression-free survival and longer time to treatment failure compared to gefitinib as first-line treatment in patients with advanced EGFR mutated NSCLC 21/01/2016 New era - new anticoagulation therapy now available in Central and Eastern Europe. Currently, dabigatran is the only DAnonVKA for which a specific counteracting agent is available: idarucizumab 15/12/2015 Sanofi and Boehringer Ingelheim have entered into exclusive negotiations for the swap of the company's assets Press releases Over-the-counter products Over-the-counter products Prescription drugs Prescription drugs Pet products Pet products up Oncology Cancer Research Program BI is an Ashoka partner More for health Distinction for BI Forbes Diamond Disclaimer Print the page Rights © 2021 Boehringer Ingelheim Sp. z o. o. All rights reserved. The requested content cannot be loaded. Please try again later.